Anti‐ IgLON5 Disease: A Systematic Review and Meta‐Analysis
European Journal of Neurology · 2025-12 · 32 (12)
DOI: 10.1111/ene.70465 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift European Journal of Neurology, online erschienen am 09.12.2025. Verfasst von Anna Grossauer und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Klinik Ottakring, Vienna, Austria. Hauptthemen laut MEDLINE: Cell Adhesion Molecules, Neuronal, Autoantibodies, GPI-Linked Proteins. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
Anti‐IgLON5 disease is now considered a complex and heterogeneous neurological disorder with sleep, movement, and neuroimmunological as well as neurodegenerative aspects. The aim of this systematic review and meta‐analysis was to entail the whole clinical spectrum as well as laboratory characteristics, therapeutic interventions and reported outcomes of anti‐IgLON5 disease.
Methods
The electronic databases PubMed/MEDLINE, Web of Science and Semantic Scholar were searched for case reports and case series on anti‐IgLON5 disease published until July 31, 2024. For inclusion, studies had to report on patients with a positive IgLON5 antibody titer in serum or CSF and be published in English in a peer‐reviewed journal. For meta‐analyses, only case series with N ≥ 10 patients were considered. The risk of bias was assessed with the JBI critical appraisal tool.
Results
A total of 285 patients ( N case series/case reports = 85) with anti‐IgLON5 disease were included in this systematic review. Sleep abnormalities ( N = 218; 76.5%), bulbar dysfunction ( N = 175; 61.4%) and movement disorders ( N = 160; 56.1%) were most frequently reported. The prevalence of IgLON5 antibodies in the serum was 99.6% ( N reported = 276).
Conclusion
Based on our results, anti‐IgLON5 disease should be considered in patients presenting with sleep disorders and additional neurological symptoms that might resemble other diseases but do not fulfill the respective diagnostic criteria. Testing for antibodies in serum has a high sensitivity in this disorder. A limitation of this study is that it was not preregistered.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Klinik Ottakring, Vienna, Austria.
- Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria.
- Department of Psychiatry, Medical University of Innsbruck, Innsbruck, Austria.
- Department of Neurology, Bezirkskrankenhaus Kufstein, Kufstein, Austria.
- Department of Neurology, Johannes Kepler University Linz, Linz, Austria.
ORCID-Profile: Anna Grossauer, Klaus Seppi, Harald Hegen
Zitieren
APA
Grossauer, A., Barket, R., Krismer, F., De Cleene, N., Heim, B., Seppi, K., Hegen, H., & Heidbreder, A. (2025). Anti‐ IgLON5 Disease: A Systematic Review and Meta‐Analysis. European Journal of Neurology, 32(12). https://doi.org/10.1111/ene.70465
Vancouver
Grossauer A, Barket R, Krismer F, De Cleene N, Heim B, Seppi K, et al. Anti‐ IgLON5 Disease: A Systematic Review and Meta‐Analysis. European Journal of Neurology. 2025;32(12). doi:10.1111/ene.70465
BibTeX
@article{Grossauer2025,
author = {Grossauer, Anna and Barket, Robert and Krismer, Florian and De Cleene, Nicolas and Heim, Beatrice and Seppi, Klaus and Hegen, Harald and Heidbreder, Anna},
title = {Anti‐ IgLON5 Disease: A Systematic Review and Meta‐Analysis},
journal = {European Journal of Neurology},
year = {2025},
volume = {32},
number = {12},
doi = {10.1111/ene.70465}
}
EUVIMED